1. Polymorphisms/Haplotypes in DNA Repair Genes and Smoking: A Bladder Cancer Case-Control Study
   Giuseppe Matullo et al, 2005, Cancer Epidemiology, Biomarkers & Prevention CrossRef
2. Relationship BetweenERCC1Polymorphisms, Disease Progression, and Survival in the Gynecologic Oncology Group Phase III Trial of Intraperitoneal Versus Intravenous Cisplatin and Paclitaxel for Stage III Epithelial Ovarian Cancer
   Thomas C. Krivak et al, 2008, Journal of Clinical Oncology CrossRef
3. Excision Repair Cross-Complementation Group 1 Polymorphism Predicts Overall Survival in Advanced Non-Small Cell Lung Cancer Patients Treated With Platinum-Based Chemotherapy
   Wei Zhou et al, 2004, Clinical Cancer Research CrossRef
4. Genetic polymorphisms as potential pharmacogenetic biomarkers for platinum-based chemotherapy in non-small cell lung cancer
   Hilary Sito et al, 2024, Molecular Biology Reports CrossRef
5. Association of ERCC1 rs11615 Polymorphism with the Risk of Cervical Cancer Especially in Chinese Populations: A Meta-Analysis
   Yufeng Zhang et al, 2022, Journal of Oncology CrossRef
6. ERCC1 and Clinical Resistance to Platinum-Based Therapy
   Eddie Reed, 2005, Clinical Cancer Research CrossRef
7. Pharmacogenetics research on chemotherapy resistance in colorectal cancer over the last 20 years
   Mariusz Panczyk, 2014, World Journal of Gastroenterology CrossRef
8. Excision Repair Cross Complementation Group 1 Single Nucleotide Polymorphisms and Nivolumab in Advanced Non-Small Cell Lung Cancer
   Marco Maria Aiello et al, 2020, Frontiers in Oncology CrossRef
9. Germline and Somatic Pharmacogenomics to Refine Rectal Cancer Patients Selection for Neo-Adjuvant Chemoradiotherapy
   Elena De Mattia et al, 2020, Frontiers in Pharmacology CrossRef
10. Impact of Gene Polymorphisms on Clinical Outcome for Stage IV Melanoma Patients Treated with Biochemotherapy: An Exploratory Study
    Dongxin Liu et al, 2005, Clinical Cancer Research CrossRef
11. Excision repair cross-complementing group-1 (ERCC1) induction kinetics and polymorphism are markers of inferior outcome in patients with colorectal cancer treated with oxaliplatin
    Devika Rao et al, 2019, Oncotarget CrossRef
12. Association between the ERCC1 polymorphism and platinum-based chemotherapy effectiveness in ovarian cancer: a meta-analysis
    Ning Tang et al, 2017, BMC Women's Health CrossRef
13. Genetic polymorphisms of GSTP1, XRCC1, XPC and ERCC1: prediction of clinical outcome of platinum-based chemotherapy in advanced non-small cell lung cancer patients of Bangladesh
    Most. Umme Bushra et al, 2020, Molecular Biology Reports CrossRef
14. Gene-Smoking Interaction Associations for the ERCC1 Polymorphisms in the Risk of Lung Cancer
    Wei Zhou et al, 2005, Cancer Epidemiology, Biomarkers & Prevention CrossRef
15. Platinum Resistance in Ovarian Cancer: Role of DNA Repair
    Giovanna Damia et al, 2019, Cancers CrossRef
16. ERCC1 Codon 118 Polymorphism Is a Predictive Factor for the Tumor Response to Oxaliplatin/5-Fluorouracil Combination Chemotherapy in Patients with Advanced Colorectal Cancer
    Jérôme Viguier et al, 2005, Clinical Cancer Research CrossRef
17. Correlation of CDA, ERCC1, and XPD Polymorphisms with Response and Survival in Gemcitabine/Cisplatin–Treated Advanced Non–Small Cell Lung Cancer Patients
    Carmelo Tibaldi et al, 2008, Clinical Cancer Research CrossRef
18. DNA-repair ERCC1 Gene Polymorphisms in Epithelial Ovarian Cancer and Relation to Platinum Resistance and Survival
    Karina Dahl Steffensen et al, 2011, Journal of Cancer Therapy CrossRef
19. ERCC1 Genotype and Phenotype in Epithelial Ovarian Cancer Identify Patients Likely to Benefit From Paclitaxel Treatment in Addition to Platinum-Based Therapy
    Stephanie Smith et al, 2007, Journal of Clinical Oncology CrossRef